RxDoctor Payments Data

Adil Ali, MD

Nephrology · Houston, TXNPI 1396062600

Payments from drug & device makers

$6,891in general payments, 2019–2025

Across 351 payments — averaging $19.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$875
  • ANI Pharmaceuticals, Inc.$609
  • Amgen$592
  • Otsuka America Pharmaceutical, Inc.$519
  • Vifor Pharma, Inc.$491
  • Bayer$471
  • plus $3K from 24 others

What the payments were for

  • Food & beverage$6,83699%
  • Education$541%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,891 in reported general payments places this provider in the 75th percentile of 1,070 nephrology providers in Texas.

See all nephrology providers in Texas

Medicare billing

Part B allowed, 2024
$249,096
Medicare patients
429
Services billed
1,899

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol300$215,354
KerendiaFinerenone128$111,451
LokelmaSodium Zirconium Cyclosilicate102$49,959
VeltassaPatiromer Calcium Sorbitex74$49,551
VelphoroSucroferric Oxyhydroxide13$39,711
JardianceEmpagliflozin54$34,866
ProcritEpoetin Alfa15$22,454
Sevelamer Carbonate55$7,886
EliquisApixaban12$7,177
Midodrine Hcl33$6,173
EdarbiAzilsartan Medoxomil12$4,128
Nifedipine ErNifedipine73$2,835
Calcitriol188$2,705
Allopurinol124$1,960
Valsartan80$1,873

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$875$265,314402 claims
BayerKerendia$471$111,451128 claims
Fresenius USA Marketing, Inc.Velphoro$264$39,71113 claims
Boehringer IngelheimJardiance$198$34,86654 claims
Johnson & JohnsonProcrit$45$22,45415 claims
ANI Pharmaceuticals, Inc.Valsartan$609$1,87380 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,070 nephrology providers in Texas.

Other nephrology in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →